Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
about
Quantification of HER family receptors in breast cancerHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenHer2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancerBreast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic CoQuantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumorsDetermination of HER2 amplification status on tumour DNA by digital PCRIn the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer.The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be tDiscordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerPractical implications of gene-expression-based assays for breast oncologists.The analytical validation of the Oncotype DX Recurrence Score assayMolecular profiling for breast cancer: a comprehensive review.High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy.Update on HER2 testing for breast and upper gastrointestinal tract cancers.The human epidermal growth factor receptor 2 (HER2).The present and future of gene profiling in breast cancer.Mechanisms underlying mutational signatures in human cancers.Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR.ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.Divisional role of quantitative HER2 testing in breast cancer.Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
P2860
Q27015506-17705674-9A7C-47FB-9CE8-F134BEDFB7CFQ28077637-262A622D-D677-45D0-B2C6-E9D3625EE25AQ33623561-6183E818-DBB7-4E9D-8FD9-3C24765C5BA1Q33862786-9E577B60-F278-42FF-93F0-7DFD19D4FF98Q33863328-78AEE63E-C6E5-4CD2-925D-1A9E472DB7F0Q33915023-7D6FDA12-1014-43A4-8AC2-2436D344BFD9Q34248282-0E2F3AFF-20E1-41E8-9DA1-3B3A237AC572Q34615545-E8B51E43-C61E-4EAA-ABA9-326AFA3BDF08Q34640536-352C74DC-0E4C-4A28-BD0A-1681DB6CBDC9Q35029573-AFFC3E87-5944-4F88-BA42-383EEEC9869CQ35078859-60346855-3429-4EAA-84BA-371F307D3FC6Q35080338-1398734C-F81E-4811-8BA8-F469E1E743E9Q35345516-B0AE3B1B-6F28-4EF1-9E9F-BA390F248489Q35687465-0EE38F7F-58DA-4518-970E-7F467E40E7DAQ35909719-82667F97-F1D6-4641-85D3-47689E120446Q35983341-4E34529C-1640-4E37-A725-3A9CDF426AA3Q36110190-333A737E-E82F-4650-BE37-F99578A8A401Q36551617-2AECEE72-A535-4B50-8B10-6C3564B23C56Q36603829-B1B25B82-8F0D-4DBC-B81F-DDEB029CC272Q36610188-AFFC54EF-F05B-4692-9D05-F101C9593B9CQ36804888-174D24E6-1081-407E-9206-DE4FF95D38EDQ36903047-066B4534-F421-4914-ABDB-55BDECC3E9BDQ36989546-681447E5-D376-4F88-B452-B7128695BC32Q37301556-DBD19D2E-1483-4B73-A021-31370A35A1A6Q37302484-2103DFEA-45B5-40D3-A0B9-C81246BB8AD9Q37671966-34572DBA-C69C-4BDA-AAE7-670272EF563AQ37863628-6824AD43-F9D5-4C6B-B77A-B23AB1DD63A0Q37886993-252FD945-FCDA-443F-B49C-7812BF6D7A87Q37932507-213312E0-488C-439F-AF93-ECC66538B4F4Q37962377-95ECC4BB-855C-4C20-A971-038374BABD33Q38225013-2F7C733F-E8C0-47F9-AA6D-975D9808F08FQ38236904-914E282F-8565-4018-B891-EADE82CFA043Q38326102-BC04EB71-5C3D-4658-B619-12BF71E0C14EQ38612634-0014CD2C-BB92-4B4D-B0B4-FCF6877CB151Q40118714-D1EDEEC5-5F52-4318-92BF-2515064214A9Q45398520-1E2D8B9F-EDAC-45F0-A960-1645794C58D3Q46521614-17A57931-E78F-4657-A827-68638E85C0EBQ47228148-629E6EB3-5AD9-4B05-A32D-47C388D648DFQ50114923-BD0BB36D-55AB-465D-9E24-0D7E912BACD2Q51663878-3A564AEF-05AB-4C6C-9655-D6CCB7620158
P2860
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Human epidermal growth factor ...... ormed by central laboratories.
@en
Human epidermal growth factor ...... ormed by central laboratories.
@nl
type
label
Human epidermal growth factor ...... ormed by central laboratories.
@en
Human epidermal growth factor ...... ormed by central laboratories.
@nl
prefLabel
Human epidermal growth factor ...... ormed by central laboratories.
@en
Human epidermal growth factor ...... ormed by central laboratories.
@nl
P2093
P356
P1476
Human epidermal growth factor ...... formed by central laboratories
@en
P2093
Allen M Gown
Charles P Quesenberry
Frederick L Baehner
Lynn C Goldstein
Ninah Achacoso
Steve Shak
Tara Maddala
P304
P356
10.1200/JCO.2009.24.8211
P407
P577
2010-08-09T00:00:00Z